Macrogen Inc

Macrogen Inc has a liquidity position that is marginally constrained, with a current ratio of 0.82, indicating that its current liabilities exceed its current assets. The company holds KRW 47.5 billion in cash and equivalents, but this is offset by KRW 101.5 billion in long-term debt, resulting in a net cash position that is negative. The debt-to-equity ratio of 0.65 suggests a moderate reliance on debt financing, but the company's free cash flow of -KRW 22.8 billion indicates that it is not generating sufficient cash to cover capital expenditures and operating needs. Profitability metrics for Macrogen Inc are mixed. The company reported a net income of KRW 2.03 billion, but its operating income was negative at KRW -544.1 million, indicating operational inefficiencies. Return on equity (ROE) is at 1.29%, and return on assets (ROA) is 0.58%, both of which are below the industry median for biotechnology and medical research firms. Gross profit of KRW 70.2 billion represents a 36% margin, which is in line with industry norms, but the company's operating margin is negative, signaling pressure on cost control. The company's revenue is primarily concentrated in its domestic market, with no disclosed breakdown of geographic exposure. However, the absence of a clear geographic diversification strategy may expose the company to regulatory and economic risks in South Korea. Macrogen Inc operates in a single business segment focused on genome analysis and related services, with no material diversification into other therapeutic or diagnostic areas. Looking ahead, Macrogen Inc is expected to see a modest increase in revenue, with analysts forecasting a mean EPS of KRW 1,028 compared to the last actual EPS of KRW 187. However, the company's operating cash flow of KRW 22.3 billion and negative free cash flow suggest that it is not yet generating sufficient cash to sustain operations without external financing. The company's capital expenditures of KRW 36.0 billion indicate ongoing investment in infrastructure, but this is not being offset by positive cash generation. The risk assessment for Macrogen Inc highlights a medium liquidity risk due to its current ratio and negative net cash position. The company's dilution risk is rated as low, with no significant dilution potential in the near term. However, the company's reliance on debt financing and negative operating income raise concerns about its long-term financial stability. Recent filings and transcripts indicate that Macrogen Inc is focused on expanding its genome analysis services and investing in new technologies such as single-cell and metagenome analysis. The company has also been involved in the production of genetically engineered mice and clinical genome analysis services, which are key growth areas in the biotechnology sector. However, the company has not disclosed any major strategic partnerships or new product launches in the latest filings.